Managing Metoprolol and Albuterol Interaction

Key Considerations for Patient Management

The European Society of Cardiology recommends that beta-blockers are not contraindicated in COPD patients, and cardioselective β1-antagonists like metoprolol are preferred 1, 2.
The European Society of Cardiology suggests starting with low doses of cardioselective beta-blockers combined with close monitoring for airway obstruction in COPD patients 1, 2.
Asthma is only a relative contraindication to beta-blocker use, not absolute, according to the European Society of Cardiology, and beta-blockers should only be used under close medical supervision by a specialist 1, 2.
The American Heart Association recommends monitoring for signs of airway obstruction, such as wheezing, increased shortness of breath, and lengthening of expiration, in patients taking metoprolol 1, 2.
The European Society of Cardiology advises monitoring heart rate and blood pressure at each visit for patients taking metoprolol 4.
The British Thoracic Society warns that beta-blocking agents, including eyedrop formulations, should be avoided in COPD patients 6.

The American College of Cardiology recommends starting metoprolol tartrate at 25 mg twice daily and metoprolol succinate at 50 mg once daily 3.
The European Society of Cardiology suggests considering administering metoprolol in smaller doses three times daily instead of larger doses twice daily to avoid higher plasma levels associated with longer dosing intervals 3.

The European Society of Cardiology states that active asthma or reactive airways disease is an absolute contraindication for IV metoprolol 5.
The British Thoracic Society warns that propranolol reduced FEV1 and hampered the fast bronchodilating effect of formoterol, and both metoprolol and propranolol increased airway hyperresponsiveness 6.